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Cancer-related death is increasing in its importance in the developed world. In 
2017, the ‘Statistisches Bundesamt’ documented 932,263 disease-related 
cases of death in Germany, 24.4% being the lethal result of malignant 
neoplasms. Only cardiovascular diseases surpassed this with more disease-
related deaths (38,5%) (Statistisches Bundesamt 2020). 
The ‘Top 5’ locations of these lethal malignancies in Germany in 2017 were 
lung/bronchia (19.1%), mammary gland (7.9%), pancreas (7.6%), colon 
(6.7%) and prostate (male: 11.0%). Pancreatic neoplasms present with a low 
prevalence, but a deflating relative 5-year survival rate of 9%, which is by far 
the lowest rate of all cancers (Statistisches Bundesamt 2020). By 2030, 
pancreatic ductal adenocarcinoma (PDAC) is expected to become the second 
leading cause of cancer-related death, after non-small cell lung carcinoma 
(Valle et al. 2018). 
Up to 10% of PDAC cases have a hereditary background including familial 
pancreatic cancer (FPC), hereditary tumour predisposition syndromes 
and tumour syndromes with chronic inflammation dysfunction of the 
pancreas (Bartsch, Gress, and Langer 2012). Members of FPC families have 
an at least 5- to 10-fold increased risk of PC, but the causative germline 
mutations have been identified in only 10% to 15% of the FPC families (Slater 
et al. 2014). 
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1.2 Pancreatic Ductal Adenocarcinoma (PDAC) 
1.2.1 Anatomy 
The pancreas is a combined exocrine and endocrine gland, located secondary 
retroperitoneal in the epigastric abdominal area, near to the upper lumbar 
vertebrae. The pancreas is macroscopically classified into head, neck, body 
and tail. 
The exocrine part of the pancreas, consisting of pyramidal acinar cells 
surrounded by connective tissue, producing an all serous digestion-secretion, 
dominates with over 90% of the volume of the gland. Vagus nerve stimulation 
or cholecystokinin secretion by enteroendocrine cells of duodenum and 
jejunum result in the secretion of the pancreatic juice, which contains several 
proteatic proenzymes (Trypsin, Chymotrypsin, Carboxypeptidase A and B) 
and Phospholipase A. The pancreatic juice enzymes are needed for digestion 
of proteins, lipids and carbohydrates in the small intestine. The secretion flows 
through the intercalated duct into the intra- and interlobular excretory duct. 
These end at the duct of Wirsung (main pancreatic duct) where the secretion 
from the pancreatic tail and the pancreatic neck flows through the ampulla of 
Vater (hepatopancreatic ampulla) from the lower part of pancreatic head finally 
through the major papilla into the duodenum. The upper part of the pancreatic 
head may drain the produced pancreatic juice through the accessory duct of 
Santorini and the minor papilla into the duodenum.  
The ductal epithelial layer of the proximal intralobular duct consists of cuboidal 
cells developing into columnar cells as they approach the distal interlobular 
duct. Furthermore, there are some isolated mucus-producing goblet cells and 
enterochromaffin cells found in between the epithelial cells. The intralobular 
duct epithelial cells have a highly concentrated cytosolic carboanhydrase and, 
basolaterally, a very active Na/K-ATPase which allows these cells to secrete 
bicarbonate in response to the hormone secretin from the small intestinal 
mucosa. The ductal epithelial cells may have apical microvilli and cilia that aid 
in fluid flow.  
Thus, the pancreatic ductal system produces an alkaline fluid, containing 
bicarbonate and mucus, that transport the acinar cell pro-enzymes into the 
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duodenum where the acidic gastric juice can be neutralized and the inactive 
enzymes can be activated (Zilles and Tillmann 2010). 
The endocrine part of pancreas consists of about 1-2 million isolated cell 
aggregations, called islets of Langerhans. Each islet is 100-200 μm in 
diameter and contains about 2,000 to 3,000 cells producing different hormones 
(Zilles and Tillmann 2010): 
•  70 % B-cells producing insulin 
•  20 % A-cells producing glucagon 
•    5 % D-cells producing somatostatin 
• < 5 % PP-cells producing the pancreatic polypeptide.  
Tumours developing from the endocrine part of pancreas are called Pancreatic 
Neuroendocrine Tumours (PNETs), but they are relatively rare in comparison 
to PDAC (Lee, Kim, and Kim 2017). 
 
1.2.2 Aetiology and risk factors 
The majority of pancreatic neoplasms are localized to the pancreatic head 
(80%) (Siewert, Rothmund, and Schumpelick 2010). The principal histologic 
subtype of pancreatic cancer is ductal adenocarcinoma, the second most 
prevalent subtype, but even much lower, are pancreatic neuroendocrine 
tumours. PDAC is described as a disease with a higher incidence in the 
western and industrial world due to life style, but there is also a difference in 
the incidence resulting from geographical and ethnic origin (Adler et al. 2007). 
The most important factor for predisposition is age, as PDAC is diagnosed with 
an average diagnose-age of 67 years for male and accordingly 74 for female 
patients (Seufferlein and Adler 2009). Additional risk factors for PDAC include 
diabetes mellitus, chronic pancreatitis, obesity, a family history of pancreatic 
cancer and a history of smoking or alcohol consumption (Kamata et al. 2017).  
 
1.2.3 Carcinogenesis 
PDAC, the most common type of pancreatic cancer, originates in cells of the 
exocrine pancreas through a malignant transformation (Seufferlein and Adler 
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2009). The ductal differentiation of the carcinoma led to the theory that the 
carcinoma develops from terminally differentiated ductal cells as opposed to 
undifferentiated pancreatic stem-cells (Valle et al. 2018). 
Similar to other epithelial carcinomas, PDAC develops from precursor lesions, 
called pancreatic intraepithelial neoplasia (PanIN). Intraductal papillary 
mucinous neoplasm (IPMN) and mucinous cystic neoplasm (MCN) can also 
develop into PDAC in rare cases (Brand et al. 2007). The PanIN classification 
divides lesions into benign neoplasia (PanIN 1), papillary lesions with low 
grade dysplasia (PanIN 2) and non-invasive carcinoma (PanIN 3/ Carcinoma 
in situ) with high grade dysplasia.  
This histological classification is accompanied by typical mutations: K-ras 
often mutates early and remains in a permanently active state, mostly due to 
a missense point mutation, which is estimated to be an initial event of 
pancreatic cancerogenesis. Another important event is the inactivation of the 
tumour suppressor-gene, CDKN2, encoding the INK-protein p16 that is 
important for cell-cycle regulation in the G1-phase. Inactivation of the tumour 
suppressor p53, important for initiation of DNA-repair and apoptosis, is also a 
very important and frequently detected event in carcinogenesis (Siewert, 
Rothmund, and Schumpelick 2010). 
 
Figure 1: Model of tumour progression: Adenoma-carcinoma sequence, with PanIN 
classification and several mutated genes 
 
Source: Siewert, Rothmund, and Schumpelick 2010 
 
 5 
1.2.4 Hereditary cancer syndromes with increased PDAC risk 
Hereditary breast-ovarian cancer (HBOC) syndrome is thought to be 
caused mainly by mutations in BRCA2 and BRCA1 genes, especially when 
the cancer is diagnosed at a young age (Ford et al. 1998). The PDAC risk of 
HBOC patients with BRCA1 germline mutations is controversial, BRCA2 
mutations are described with an increased relative risk in the range of 2.3 to 7 
(Carrera et al. 2017). PALB2 germline mutations also go along with a 5- to 9-
times increased risk of breast cancer (Antoniou et al. 2014), truncating variants 
are also detected in PDAC patients, assuming to be causing there pancreatic 
carcinoma (Slater, Langer, Niemczyk, et al. 2010). 
Pancreatic cancer melanoma syndrome (PCMS; Familial atypical multiple 
mole melanoma, FAMMM) is caused mainly by CDKN2A germline mutations, 
although other genes such as CDK4 and BAP1 have been associated with 
this syndrome (Carrera et al. 2017). The PDAC risk rises up to 17% (at p16-
Leiden mutation: 19bp deletion in exon 2 of CDKN2A) depending on the 
pathogenetic variant of the CDKN2A mutation (Vasen et al. 2000). 
Peutz-Jeghers syndrome (PJ) results from mutations in the STK11/LKB1 
gene. Phenotypically, it is characterized by mucocutaneous pigmentation, and 
pathognomonic intestinal hamartomatous polyps. PJ-patients have a 
cumulative lifetime risk for PC of 11% and there is also an increased risk for 
cancers of the colon, stomach, small intestine and breast (Carrera et al. 2017). 
Familial adenomatous polyposis (FAP) is an autosomal dominant entity 
characterized by hundreds to thousands of adenomas throughout the colon. 
FAP patients have a risk of developing colorectal carcinoma by the fourth 
decade of life that is nearly 100% (Waller, Findeis, and Lee 2016). FAP 
syndrome is caused by mutations in the APC (adenomatous-polyposis-coli) 
gene. Mutations in this tumour suppressor gene result in a PDAC relative risk 
that is 4.5 times higher than for the general population (Moussata et al. 2015). 
Lynch syndrome (LS, Hereditary non polyposis colorectal cancer) develops 
due to germline mutations in mismatch repair system genes (MLH1, MSH2, 
MSH6, PMS2) and it represents the most common cause of hereditary 
colorectal cancer (Carrera et al. 2017). There is a 9-fold increased PDAC risk 
for mutation carriers (Kastrinos et al. 2009). 
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Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer 
predisposition condition characterized by the development of a wide spectrum 
of malignancies (most frequently breast cancer, sarcomas, brain tumours and 
leukemia). LFS is caused by germline mutations in p53 gene (Carrera et al. 
2017). It is estimated that approximately 50% of the individuals with LFS will 
develop cancer by the age of 30 years (Correa 2016). The relative risk for 
developing PDAC is increased nearly 7-fold (Ruijs et al. 2010). 
 
1.2.5 Hereditary pancreatic dysfunction syndromes with increased PDAC 
risk 
Hereditary pancreatitis (HP) is an extremely rare diagnosis and comes with 
a 50- to 70-fold increased relative risk for PDAC as compared to the general 
population (Howes, Lerch, et al. 2004). Approximately 80% of HP patients host 
pathogenic variants in PRSS1 gene (encoding cationic trypsinogen) that leads 
to an activation of trypsinogen inside the pancreas with auto digestion of the 
gland, thus causing an inflammation (Howes, Greenhalf, et al. 2004). SPINK1 
(serine peptidase inhibitor) gene encodes a trypsin inhibitor that is secreted by 
the pancreatic acinar cells and mutations in SPINK1 are also associated with 
an increased HP risk (Carrera et al. 2017). 
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis 
transmembrane regulator (CFTR) gene, that disrupt the localization and 
function of the cAMP-mediated chloride channel, resulting in an obstruction of 
pancreatic ducts by mucus secretions (Fendrich, Langer, and Bartsch 2014). 
It is estimated that 1.5% of all CF patients will suffer pancreatitis, potentially 
increasing the risk of PDAC development (Carrera et al. 2017). 
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1.3 Familial pancreatic cancer (FPC) syndrome 
1.3.1 Definition 
FPC syndrome describes an established entity of inherited PDAC (Zhen et al. 
2015). Families with FPC have two or more first-degree relatives (sibling-
sibling or parent-child) with PDAC (Bartsch et al. 2004) and do not fulfil the 
criteria for another inherited syndrome (Slater, Langer, Niemczyk, et al. 2010). 
FPC is a rare but established inherited tumour predisposition syndrome (Zhen 
et al. 2015). Members of FPC families carry a 2.3- to 32-fold increased PDAC 
risk, depending upon the number of affected family members (Klein et al. 
2004). 
In the following, the term ‘hereditary pancreatic cancer’ will be used to refer to 
a familial accumulation of pancreatic cancer. The genetically background 
therefore may be based on the above defined FPC syndrome, other hereditary 
tumour syndromes or other hereditary dysfunction syndromes of the pancreas, 
both not fulfilling the definition of FPC syndrome. 
 
1.3.2 ‘Nationale Fallsammlung Familiäres Pankreaskarzinom der Deutschen 
Krebshilfe’ – FaPaCa 
The ‘FaPaCa’ case registry for FPC and PCMS patients, as well as their 
relatives, was established in 1999 at the Universitätsklinikum Marburg/ 
Philipps-Universität Marburg, Germany (Bartsch et al. 2001). FaPaCa collects 
and evaluates the phenotype of FPC families, perform a board-approved 
clinical screening program for the early detection of PDAC and its high grade 
precursors and aims to identify additional FPC susceptibility genes. 
For a family to be included in the study, there must be at least two first-degree 
relatives with PC (FPC), or one PC and one melanoma in the family (PCMS), 
without fulfilling the criteria for other hereditary tumour predispositions 
syndromes such as HBOC, according to the FPC definition in section 1.3.1. 
Three PDAC patients in one family, independent of the relationships, or a 
detected BRCA1/2 mutation with at least one PDAC in the family, also qualifies 
for enrollment in the FaPaCa registry. 
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The FaPaCa registry contains over 200 families with over 500 affected 
persons. The known pathogenic variants in some families include the genes 
BRCA2, BRCA1, PALB2, CDKN2A and CHEK2. 
High risk relatives are offered annual screening in a controlled study in FPC 
centres starting at an age ten years earlier than the youngest PDAC diagnosis 
in the family or at 40 years of age (Langer et al. 2009)  (Bartsch et al. 2016). 
 
1.3.3 Susceptibility genes 
Five genes have yet been established as low-penetrance FPC susceptibility 
genes. These include: 
• BRCA1 (Al-Sukhni et al. 2008) 
• BRCA2 (Murphy et al. 2002) (Hahn et al. 2003) 
• CDKN2A (Slater, Langer, Fendrich, et al. 2010) (Zhen et al. 2015) 
• PALB2 (Slater, Langer, Niemczyk, et al. 2010) 
• CHEK2 (Bartsch et al. 2006) 
Few other genes have been reported to be potential FPC predisposition genes: 
The Pancreatic Cancer Genetic Epidemiology (PACGENE) Study 
(ClinicalTrials.gov Identifier: NCT00526578) described a prevalence of 8% of 
all pathogenic variants among the 521 included FPC patients in previously 
identified FPC susceptibility genes (BRCA1, 1.2%; BRCA2, 3.7%; PALB2, 
0.6% and CDKN2A 2.5%) (Zhen et al. 2015). 
A whole genome sequencing project from Roberts et al., using germline DNA 
of 638 FPC patients from 593 families, analysed 87 genes that included all 
susceptibility genes for hereditary pancreatic cancer (Roberts et al. 2016). The 
previously reported FPC susceptibility genes frequently contained deleterious 
mutations, which underscores their importance. Furthermore, they detected a 
large number of private heterozygous Premature Truncating Variants (PTV), 
whose role in the heterogenic origin of FPC needs to be confirmed (Roberts et 
al. 2016). As new candidate genes are named ATM, BUB1B, CPA1, FANCC, 
FANCG, POLN, POLQ and APC, which contain more deleterious variants in 
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FPC patients than in controls. The frequency of detected mutations in the 
known genes associated with hereditary pancreatic cancer is difficult because 
patients with known deleterious variants in the common FPC susceptibility 
genes BRCA1, BRCA2, CDKN2A and PALB2 were excluded to maximize the 
opportunity to discover novel susceptibility genes (Roberts et al. 2016). 
In 2018, Chaffee et al. published their results of sequencing from 25 cancer 
susceptibility genes in lymphocyte DNA from 185 FPC patients (Chaffee et al. 
2018). Of these 185 patients, 25 (14%) carried deleterious mutations in genes 
known to be associated with PDAC: BRCA2 4.3%, BRCA1 1.1%, CDKN2A 
2.2%, ATM 3.2%, PALB2 0.5%, MSH 0.5%, PMS2 0.5%, CHEK2 0.5% and in 
genes not known to be associated with PDAC: BARD1 0.5%, NBN 0.5%) 
(Chaffee et al. 2018). 
The results from a Japanese study are quite similar to those of the Western 
countries. They published the findings of eight deleterious mutations found in 
54 FPC patients (14.5%): BRCA2 (3 mutations), PALB2 (2), ATM (2) and 
MLH1 (1). 
MLH1, MSH2, MSH6 (all known from HNPCC), PMS2 (HNPCC), PRSS1 (HP), 
STK11 (PJS), and p53 (LFS) are also named as possible PC susceptibility 
genes (Roberts et al. 2016), but only analysed in patients with pancreatic 
cancer based on hereditary tumour syndromes, not fitting to the FPC definition. 
The genetic basis underlying disease susceptibility in the remaining 80 – 90% 
of FPC patients is unknown (Roberts et al. 2016). 
Identifying further FPC susceptibility genes that are responsible for the 
inheritance of increased PDAC risk is important for many reasons: screening 
of family members carrying the mutation(s) might allow the detection of 
suspect pancreatic neoplasms in an earlier state when preventive resection of 
precursor lesions or therapeutic options with curative potential are still 
available (Bartsch et al. 2016). A newly published multi-analytic blood test 
offers the possibility of early detection of the rapidly growing PC (Cohen et al. 
2018). This test combines protein biomarkers with genetic biomarkers and is 
able to detect the presence of some common solid tumour types (e.g. PDAC). 
Unfortunately, it was only tested on diagnosed tumour patients and cannot be 
safely applied for the detection of the less severe and potentially rapidly 
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growing precursor lesions like PanIN 2-3 (Cohen et al. 2018). Cohen 
recommends using additional cancer biomarkers, such as metabolites, mRNA 
transcripts, miRNAs, or methylated DNA sequences to increase sensitivity and 
localization of cancer site. Knowing FPC susceptibility genes is important, 
because FPC susceptibility genes also increase risk for extra pancreatic 
neoplasm, which then might be screened as well (Wang et al. 2009). In 
addition, in some FPC families PDAC develops earlier in subsequent 
generations because of the effect of anticipation (McFaul et al. 2006). 
Furthermore, the knowledge of the existing mutation might also lead to a 
personalized therapy, as described below in section 1.4.6. 
Genetic susceptibility also plays an important role in sporadic PDAC risk. 
Genome-wide association studies (GWAS) with over 10,000 PC patients have 
been performed with the aim of identifying additional common pancreatic 
cancer risk loci in western and Asian populations (Klein et al. 2018). Because 
of the high number of analysed PC patients and the strong association of 
mutations to PC cases, the newly identified genes (NOCL2, TNS3, HNF4G, 
HNF1B and GRP) that seem to increase PDAC risk, might also be analysed in 
FPC patients. 
 
1.4 Ataxia telangiectasia mutated (ATM) gene 
1.4.1 ATM as a target gene 
The ATM gene does not actually belong to the routinely tested susceptibility 
genes in FPC patients of the ‘FaPaCa’ case registry. However, Roberts 
published a role of pathogenic variants in ATM gene as possibly a new FPC 
susceptibility gene (Roberts et al. 2012, Roberts et al. 2016). Roberts 
described the analysis of ATM mutations in 166 FPC subjects (Roberts et al. 
2012). Considering only the more severely affected families with more than 3 
FPC patients per family, the rate of deleterious variants in ATM gene in FPC 
patients even increases from 2.4% (4/166) up to 4.6% (4/87), underlying the 
possible importance of these pathogenic variants in increasing the PDAC risk 
in these families. Besides, the families with ATM-mutations detected by 
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Roberts not only include PC patients, but also malignancies in lung, colon, 
uterus, prostate and ovaries and lymphoma and malignant melanoma. 
The fact that the tumour suppressor ATM is known to be a cancer 
predisposition gene (Rahman 2014) raises the question if analysing the ATM 
gene in all ‘FaPaCa’ patients would detect the genetic background for the 
increased PDAC-risk in some ‘FaPaCa’ case registry families. 
 
1.4.2 Human ATM gene 
The human ATM gene (NCBI Reference Sequence for gDNA: NC_000011.10) 
is made up of 66 exons, of these 62 protein coding (Uziel et al. 1996), is located 
on chromosome 11 q22-q23 (UCSC Genome Browser 2016) and spans 
150 kb of genomic DNA. The gene encodes a 350 kDa kinase, consisting of 
3065 amino acids (Weizmann Institute of Science 2018). The mRNA sequence 
NM_000051.3 is the reference standard in the NCBI Reference sequence 
(RefSeq) project, containing of 13147nt with the coding sequence from 386-
9556, describing the full length protein as it has been used for our analyses. 
The ATG start site is located in exon 2 (386- 388) and the stop codon is located 
in exon 63 (9554-9556). 
The ATM gene is named after Ataxia telangiectasia (AT), also called Louis-Bar 
syndrome, an inherited neurological disease, first described and named in 
1941 (Louis-Bar 1941). In 1995, Savitsky detected the gene that harbours 
deleterious germline mutations in cases of AT (Savitsky et al. 1995). 
 
1.4.3 ATM kinase 
The protein encoded by the ATM gene is a serine/threonine-kinase, belonging 
to the PI3/PI4-kinase-like kinase (PIKK) family and primarily located in the 
nucleus (Tripathi et al. 2016). ATM kinase plays an important role in DNA 
double-strand-break (DSB) repair and replication stress management 
(Maréchal and Zou 2013). DSBs represent the most deleterious form of DNA 
lesions that can arise spontaneously during DNA replication or as a response 
to certain exogenous hazards such as ionizing radiation (Larsen and Stucki 
2016). 
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ATM kinase phosphorylates proteins that contain Serine (S) or Threonine (T) 
residues that are followed by Glutamine (Q) (SQ or TQ motifs) (Awasthi, 
Foiani, and Kumar 2016). 
Figure 2: ATM activation at DSBs 
  
Source: Maréchal and Zou 2013 
 
Awasthi et al. (Awasthi, Foiani, and Kumar 2016) reviewed ATM activation in 
2016 and described an inactive ATM existing in the form of a homodimer or 
multimer. Awasthi reports about a MRE11– RAD50–NBS1 (MRN) complex 
acting as a sensor for DSBs and binding the dsDNA at a detected DSB. ATM 
activation then becomes stimulated by MRN complex by ATM binding MRN. 
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This contact leads to ATM auto-phosphorylation resulting in the simultaneous 
dissociation of the ATM homodimers. Research on the detailed molecular 
mechanism is still in progress. The ATM monomers are catalytically active that 
leads to a widespread phosphorylation of downstream-acting proteins which is 
the main part of activated ATM (Khalil et al. 2012).  
 
One of the key processes is the phosphorylation of the histone variant H2AX 
in the DSB flanking region by ATM, leading to an mdc1-mediated chromatin 
relaxation and binding from several DSB repair complexes (Polo et al. 2010). 
Furthermore, ATM phosphorylates checkpoint kinase 2 (CHEK2, Checkpoint 
arrest in G1 phase), p53 and many others substrates, which is required for 
accumulation of numerous DNA repair proteins and chromatin-remodelling 
complexes around the occurred DSB (Maréchal and Zou 2013), cell cycle 
arrest, chromatin remodelling or apoptosis (Khalil et al. 2012).  
 
Figure 3: ATM signalling pathway 
 
Source: adapted to Khalil et al. 2012 
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Thus, the absence of the ATM protein leads to a failure in the signalling 
network responding to DSBs and other types of genotoxic stress. The resulting 
genomic instability can cause the development of cancers (Shiloh 2003). 
 
1.4.4 Ataxia telangiectasia/ Louis-Bar-Syndrome 
Ataxia telangiectasia (AT) is a rare autosomal recessive disorder with a world-
wide prevalence between 1/40,000 and 1/100,000 live births. AT is often 
referred to as a DNA damage response syndrome where the main 
characteristics are progressive cerebellar degeneration (ataxia, postural 
instability) without mental retardation, oculomotor apraxia, telangiectasia 
(on bulbar conjunctiva and sclera), hypersensitivity to ionizing radiation, 
immunodeficiency (frequent sinopulmonary infections) and cancer 
susceptibility (particularly of lymphoid organs). The syndrome displays great 
variability in the severity of its symptoms and the age of their manifestation - 
the onset is most often in early childhood, but some neurological features may 
arise later (Rothblum-Oviatt et al. 2016). 
AT is usually diagnosed based on clinical appearance, supported by specific 
laboratory abnormalities (e.g. IgA deficiency, lymphopenia especially affecting 
T-lymphocytes and increased alpha-fetoprotein levels). Furthermore the AT 
diagnosis can be confirmed by identification of bi-allelic deleterious mutations 
in the ATM gene or finding an absence or deficiency of ATM protein or its 
kinase activity in cultured cell lines (Rothblum-Oviatt et al. 2016). 
AT patients show severe bi-allelic mutations in ATM gene, commonly they 
have compounded heterozygous mutations (Hassin-Baer et al. 1999). There 
is no area of the ATM gene especially susceptible to mutations; nonsense 
mutations, frame shift mutations caused by insertions and deletions, but also 
missense and leaky splice-site mutations have been described all over the 
gene (Telatar et al. 1998).  
AT patients have an increased incidence (about 25% lifetime risk) of cancers 
(Rothblum-Oviatt et al. 2016), most often lymphoma, leukemia, and breast 
cancer (Reiman et al. 2011). A variety of other solid tumours including liver, 
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gastric and oesophageal carcinomas known from unpublished observations 
are also described by Rothblum-Oviatt et al. (Rothblum-Oviatt et al. 2016). 
 
1.4.5 Diseases with increased prevalence at ATM germline mutations 
Relatives of AT patients, who have a heterozygous mutation in the ATM gene, 
are generally healthy (Rothblum-Oviatt et al. 2016). The reported mono-allelic 
carrier frequency of pathogenic ATM variants in the population is relatively 
common with 0.5 - 1% (Taylor and Byrd 2005) or 1.4 - 2.2 % (Khalil et al. 
2012). 
There is an increased life time risk for heterozygous ATM mutation carriers to 
develop cancer, confirmed for several entities: 
• Breast cancer (Buys et al. 2017, Athma, Rappaport, and Swift 1996) 
• Leukemia (Bullrich et al. 1999) 
• Lymphoma (Oguchi et al. 2003) 
However, a meta-analysis published in 2016 could only show that 
heterozygous carriers of a pathogenic ATM mutation have a decreased life 
expectancy and an increased risk of developing breast cancer, diabetes, and 
cardiovascular and neurodegenerative diseases. The possibility of 
developing cancer of the gastrointestinal tract could not be verified clearly and 
needs to be further investigated (van Os et al. 2016). 
 
1.4.6 Treating ATM mutated cancer with targeted therapy 
Thus, deleterious ATM mutations decrease the ATM kinase functionality, 
which leads to genomic instability through loss of DSB DNA repair. Stalled 
replication forks or unrepaired single-strand breaks (SSB) convert into DSBs 
that cannot be repaired. Based on this rationale, inhibition of other kinases 
involved in SSB DNA repair has been considered a potential mechanism for 
synthetic lethality in cancers hosting deleterious ATM mutations (Choi, Kipps, 
and Kurzrock 2016). 
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Poly(ADP-Ribose)polymerase-1 (PARP-1) is involved in repair of single-
stranded DNA breaks. When these breaks are encountered during DNA 
replication, the replication fork stalls, and double-strand DNA (dsDNA) breaks 
accumulate (Schultz et al. 2003). A study in ATM-deficient lymphoid tumour 
cells showed an increased sensitivity to PARP-1 inhibition with ‘Olaparib’ 
(Weston et al. 2010), indicating that PARP-1 inhibitors may be effective in 
ATM-deficient pancreatic tumours (Bakker and de Winter 2012). 
The ATR (ataxia telangiectasia and Rad3-related protein) - CHEK1 
(checkpoint kinase 1) pathway is another potential target for therapy in cancers 
containing deleterious ATM variants, as it is a primary sensor and mediator of 
SSB DNA repair (Choi, Kipps, and Kurzrock 2016). A synthetic lethal siRNA 
screen confirmed that mantle cell lymphoma cells with loss of ATM function 
have increased sensitivity to ATR inhibition (VE821, VE822, and AZD6738) 
(Menezes et al. 2015). CHEK1 is a serine/threonine-kinase and an important 
downstream substrate which gets phosphorylated by activated ATR. Thus, 
CHEK1 inhibitors might have the same DNA-repair blocking effect in ATM-
deficient cancer cells as ATR inhibitors have, which might lead as well to an 
increased DNA damage and cell death (Choi, Kipps, and Kurzrock 2016). 
 
1.5 The aim of the thesis 
It was the aim of this thesis to analyse the ATM gene in germline DNA from 
German FPC patients of the FaPaCa case registry in order to detect possible 
pathogenic variants that might be responsible for the increased PDAC risk in 
some of these FPC families. WGS, Sanger sequencing and MLPA were to 
identify different mutations and then it was necessary to identify the 
deleteriousnsess to distinguish pathogenic and non-pathogenic variants. The 
question finally to be answered was whether or not ‘FaPaCa’ patients should 
be screened regularly for pathogenic variants in the ATM gene, as is presently 
performed with the BRCA2, CDKN2A and PALB2 genes. 
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2 Materials and methods 
2.1 Materials 
The materials and appliances which were used are listed in the table below. 
Table 1: Appliances 
Name Manufacturer 
Centrifuge 5430 R Eppendorf, Hamburg, DE 
Dri Block DB 2A Techne, Oxford Cambridge, UK 
Eppendorf Mastercycler ep gradient 
S Thermal Cycler 
Eppendorf, Hamburg, DE 
Eppendorf Research Plus Pipette; 
1000µl,200µl,100µl, 20µl, 10µl, 2,5µl Eppendorf, Hamburg, DE 
Heraeus Biofuge Pico Thermo Fisher Scientific,Waltham,US 
Nanodrop Lite Thermo Fisher Scientific,Waltham,US 
 
Table 2: Chemicals and Enzymes 
Name Manufacturer 
Alkaline Phosphatase New England Biolabs, Frankfurt am Main, DE 
Ethanol >99.8% Sigma Aldrich, Steinheim, DE 
Exonuclease I New England Biolabs, Frankfurt am Main, DE 
GeneRuler 50 bp DNA Ladder Thermo Fisher Scientific, Osterode, DE 
GeneScan™ 500 LIZ™ dye Size 
Standard 
Thermo Fisher Scientific, 
Osterode, DE 
peqGOLD Universal Agarose Peqlab Biotechnologie GmbH, Erlangen, DE 




5.5g/L Boric acid 
0.82g/L EDTA 
 
ACROS Organics, Geel, BE 
Fisher Scientific UK, 
Leicestershire, UK 
ACROS Organics, Geel, BE 
6x DNA Loading Dye Thermo Fisher Scientific, Osterode, DE 
 18 
 
Table 3: Consumables 
Name Manufacturer 
Biosphere Filter Tips 1250µl extra 
long Sarstedt, Nürnbrecht, DE 
Biosphere Filter Tip 200, 100 Sarstedt, Nürnbrecht, DE 
Biosphere Filter Tip 2,5 farblos Sarstedt, Nürnbrecht, DE 
Multiply-Pro Gefäß 0,2 ml Sarstedt, Nürnbrecht, DE 
Reagiergefäß 1,5ml Safe Seal Sarstedt, Nürnbrecht, DE 
SafeSeal SurPhob Spitzen, 10µl, 
extra lang, steril Biozym, Hessisch Oldendorf, DE 
 
Table 4: Ready to use systems (Kits) 
Name Manufacturer 
DNeasy Blood & Tissue Kit (250) Qiagen, Hilden, DE 
ReadyMix™ Taq PCR Reaction Mix Sigma Aldrich, Steinheim, DE 
SALSA MLPA EK1 reagent kit 100 rxn 
(6 vials) - FAM 
MRC-Holland bv, Amsterdam, NL 
SALSA MLPA P041 ATM-1 probemix MRC-Holland bv, Amsterdam, NL 




Table 5: ATM Exon Sequencing Primer 





NAME LEFT PRIMER NAME RIGHT PRIMER PRODUCT SIZE (bp) 
ATM-E02-03F CTTTGACCAGAATGTGCCTC ATM-E02-03R GCCAAATTCATATGCAAGGC 585 
ATM-E04F TTTGTGATGGCATGAACAGC ATM-E04R CAAACTTATGCAACAGTTAAGTCC 336 
ATM-E05F CTTGGGGCCATAATTTGC ATM-E05R AGACAGAGTGCTTTCTTTGGTG 387 
ATM-E06F TCTGTATGGGATTATGGAATATTTAAG ATM-E06R CTGAGTCTAAAACATGGTCTTGC 336 
ATM-E07F TCAGCATACCACTTCATAACTGTTC ATM-E07R TCAACCAGAGAAATCCAGAGG 438 
ATM-E08F AATTTTGTGGGAGCTAGCAG ATM-E08R TTTTAAAAGCCCAAAATGCC 314 
ATM-E09F TCCAACCTGGGCAACAAC ATM-E09R GGTTGAGATGAAAGGATTCCAC 340 
ATM-E10F CTATGGAAATGATGGTGATTCTC ATM-E10R TGATCAGGGATATGTGAGTGTG 569 
ATM-E11F CCTTAACTAAATGTATGTGCCAGG ATM-E11R GGTTAGATCTGGGAAATTCTGC 413 
ATM-E12F GGTTGTCCTCCTTAAATTGTCC ATM-E12R AAAACAACCTCTTCCCTGGC 428 
ATM-E13F ATAAGTAGGTCTCAAAGTCCGAAG ATM-E13R CTGCCCCTATTTCTCCTTCC 487 
ATM-E14F TCCAGGATATGCCACCTTTAAC ATM-E14R AAAAGAGAAAGGGTTAACCTGC 381 
ATM-E15F TGCTTATACTGTATGACTACGTGGAAC ATM-E15R CTGGAAACCAGGAGGTCAAG 409 
ATM-E16F GAAGCAGCATATATATTGGCCC ATM-E16R CACCTGGCCTTAATTTCCAC 364 
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NAME LEFT PRIMER NAME RIGHT PRIMER PRODUCT SIZE (bp) 
ATM-E17F CACATGAACCTTGAATTGTTTG ATM-E17R AAGAAAGGAACAATCCTAAAAGG 720 
ATM-E18F GAAGAGGAGGAAATTTGAGTTAATATG ATM-E18R TCTTCAAAGACACCATGTGATTC 382 
ATM-E19-20F AAATATTTACAGCTGTGTGTGTGTG ATM-E19-20R GTTCTTCAAGCGACTGAGGG 939 
ATM-E19-20F_seq TTTTTCCCTCCTACCATCTTAGTATC  ATM-E19-20R_seq GTCCTTGAGCATCCCTTGTG 337 
ATM-E21-22F GTTTAGCACAGAAAGACATATTGG ATM-E21-22R TTGCAACTGTGAGCTGTTACTATG 516 
ATM-E23F TGCTTTGGAAAGTAGGGTTTG ATM-E23R AATCAATTCATACAGTTGTTTTAGAGC 337 
ATM-E24F AAAATCTGGAGTTCAGTTGGG ATM-E24R AGTGCCACTCAGAAAATCTAGC 349 
ATM-E25F TCAAGAAAAGTTGAATGAATGTTG ATM-E25R TGGTATGTGTGTTGCTGGTG 377 
ATM-E26F CTTTAATGCTGATGGTATTAAAACAG ATM-E26R GCCAATCAGAGGGAGACAAC 535 
ATM-E27F AGTCTACAGGTTGGCTGCATAG ATM-E27R TGTGGGGAGACTATGGTAAAAG 493 
ATM-E28F CAGTAGAAAAATGGTTTTTGAATTTG ATM-E28R TGAATGTTTTCCTTTTTAATTATGAG 383 
ATM-E29F TTGTAGCCGAGTATCTAATTAAACAAG ATM-E29R GCGGACAGAGTGAGTCTTTG 360 
ATM-E30F CTGCCTATTCTGCATTTTGC ATM-E30R AACATAAAACACTCAAATCCTTCTAAC 432 
ATM-E31F CACAGAAACTAAAAGCTGGGTATC ATM-E31R ATAGGCATGAGCCAATGTGC 469 
ATM-E32F CATTGTAGGGTTTGCAGTGG ATM-E32R TGACAATGAAACCAAGAGCAAG 391 
ATM-E33F TTGTCACATATTGCTAATCACTTTC ATM-E33R ATTGGGCAATTCTGTCATTG 528 
ATM-E34F TGGGATTACGGGCCTGC ATM-E34R TTTAACAGGGACCTTGTCTGG 679 
ATM-E35F GGAATTGCAGTTGCAGTGATTAG ATM-E35R TCTGAGCTTTTCCACACTGC 552 
ATM-E36F TGTTATACTCATTTTGTGTAGGAAAGG ATM-E36R TTTACAACAGTTTGAGTGGGG 372 
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NAME LEFT PRIMER NAME RIGHT PRIMER PRODUCT SIZE (bp) 
ATM-E37F GAAATTTAATATGTCAACGGGG ATM-E37R TCCTGTAAAGTGCTTTTAGTGGG 372 
ATM-E38F ATAGCATAGTGGGAGACAGACAC ATM-E38R TCATGTTAAAATTCAGCCGATAG 258 
ATM-E39F CAGATTCTCTGATAGGTTTGAGGG ATM-E39R TAAATGGGGAACAGGAGGC 489 
ATM-E40F TCACAAATTCCTTTTCCATCC ATM-E40R TGATGCTTAGTCCAGTAAGTAAATTC 389 
ATM-E41-42F TTGGGAGTTACATATTGGTAATGATAC ATM-E41-42R GGAGTATCCCTGAATGTTTAGCC 547 
ATM-E43F CACCCAGCTGATATTTTGGG ATM-E43R TGCTTATTGCTATCTTACTGAAGG 565 
ATM-E43F_seq TTAGGCCTTGCAGAATTTGG  ATM-E43R_seq TACCTGACGGAAGTGCAATG 156 
ATM-E44F AAATTTTGTCCTTTGGTGAAGC ATM-E44R TCTCTTCATCAATGCAAATCC 300 
ATM-E45F TTTTGTTTCCACTGCTATTTTG ATM-E45R AGTGATCCACCCACTTCAGC 424 
ATM-E46F TCTGACCGCATAGCATTTTG ATM-E46R GCCCAAGGCTTAAAAGTCAG 611 
ATM-E47F GACAGATAGGCAGACGTGGG ATM-E47R CGACCACATGATGGACTGATAG 561 
ATM-E48F GTACATGAAGGGCAGTTGGG ATM-E48R CACTCCACCCTAGAGACTATACAGAG 341 
ATM-E49F GTGGGTTGGACAAGTTTGC ATM-E49R AAAGACCAAGTCACTCTTTCTATGC 455 
ATM-E50F TTCCCTTTATAATCCTTAGAAGTTTG ATM-E50R TGTGTAGAGCACTGGACCAAG 473 
ATM-E51F CCACTTGTGCTAATAGAGGAGC ATM-E51R GAGGCCTATGAGGAATTAGAGAG 397 
ATM-E52F CGCTCTACCCACTGCAGTATC ATM-E52R CTTGAACCGATTTTAGATGGC 386 
ATM-E53F TGACTGTTTTGTTTGTATCTGAGG ATM-E53R GTAACCAGGGAATGCTGAAG 443 
ATM-E54F GGCCAGTGGTATCTGCTGAC ATM-E54R GCCAATATTTAACCAATTTTGACC 276 
ATM-E55F TCACATCGTCATTTGTTTCTCTG ATM-E55R AAGACAAAATCCCAAATAAAGCAG 350 
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NAME LEFT PRIMER NAME RIGHT PRIMER PRODUCT SIZE (bp) 
ATM-E56F TGAGTGCCCTTTGCTATTCTC ATM-E56R ATATGGGCATGAGCCACTTC 285 
ATM-E57F AAAATGCTTTGCACTGACTCTG ATM-E57R TTGACAATTACCTGATGAAATTAAAG 360 
ATM-E58F TTCCCTGTCCAGACTGTTAGC ATM-E58R TGCCAAACAACAAAGTGCTC 363 
ATM-E59F ACATGGCCGGTTATGCAC ATM-E59R TTGGTAGGCAAACAACATTCC 313 
ATM-E60F TTGCCTTTGTAAAGTTCACATTC ATM-E60R AAAGAACCATGCCCAGCC 271 
ATM-E61F AGCATAGGCTCAGCATACTACAC ATM-E61R TGAAGCAGTGCTCTTCACATC 259 
ATM-E62-63F TGTGCATGATGTTTGTTCCC ATM-E62-63R AAGAGTGAAAGCAGAGATGTTCC 766 
ATM-E62F TGACTGGCTTATTTGTATGATACTGG ATM-E62R GAACAGTTTAAAGGCCTTGGG 305 
ATM-E63F GATGACCAAGAATGCAAACG ATM-E63R AAGAGTGAAAGCAGAGATGTTCC 523 
 
Table 6: SRY-Amplicon Primer 
SRY-for: GAGTGAAGCGACCCATGAACG 
SRY-rev: CTTGAGTGTGTGGCTTTCGTACAG 
Product_size: 349bp  
Producer: Eurofins Genomics, Braunfels, Germany 
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2.2 Samples 
Germline DNA from affected PDAC patients from the FaPaCa registry has 
been used for Whole Genome Sequencing, Sanger Sequencing and MLPA. 
All coding ATM exons have been subjected to Sanger Sequencing and MLPA, 
as there is no area of the gene that is especially susceptible to mutation. 
Mutations have been identified throughout the coding region and splice sites 
(Rothblum-Oviatt et al. 2016). 
The patients chosen were taken from FPC families with the most PDAC cases 
per family. This should increase the probability of detecting a genetic reason 
causing the hereditary background as found in another studies (Roberts et al. 
2012). 
All these patients and their family members are part of the FaPaCa registry 
and gave informed consent for the genetic analysis of their blood samples (Etic 
vote: “Klinische und genetische Untersuchung des familiären exokrinen 
Pankreaskarzinoms mit Aufbau einer nationalen Fallsammlung”; Studie 36/97, 
printed in the appendix in section 8.1). The EDTA-treated blood tubes had 
been stored at -80°C until DNA extraction. 
 
2.3 DNA extraction 
DNA for the mutation analyses was extracted out of leucocytes from venous 
blood of the FPC patients using the ‘DNeasy® blood and tissue kit’. In contrast 
to the manufacturer’s protocol of the kit, we used 200μl of the anticoagulant-
treated blood (from EDTA-treated tube) to increase DNA yield and 20μl 
proteinase K taken from the used kit and added to a 1.5ml Eppendorf tube. 
PBS from the kit was not added at this step, according to the manufacturer's 
instructions. Then DNA extraction was performed as recommended in the 
‘DNeasy® Blood & Tissue Handbook’. The concentration of the DNA (eluted 
in buffer AE) was identified using NanoDrop lite by Thermo Fisher Scientific 
and stored in 1.5ml Eppendorf tubes at -20°C until further use. 
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2.4 Whole Genome Sequencing (WGS) 
WGS was performed at the DKFZ (Deutsches Krebsforschungszentrum) in 
Heidelberg initially with 3 families (13 FPC cases and 17 healthy family 
members) to identify new FPC susceptibility genes candidates. The 3 families 
had been selected because of their particularly high number of PDAC patients 
without a known mutation in FPC susceptibility genes. Later, 12 more FPC 
cases from different families were also sequenced. The data has been 
analysed in cooperation with the DKFZ Heidelberg and the Helmholtz Zentrum 
München. 
The ‘HiSeq X ten system’ from Illumina was used for WGS, as a ‘Sequencing 
by Synthesis’-method with a four-steps workflow: 
 
The ‘Sample Preparation’ started with extracted DNA that is fragmented. 
Nucleic-adaptor molecules need to be ligated to the end of the DNA fragments. 
The adaptors contain motives including primer binding sites and regions 
complementary to the flow cell oligonucleotides. The flow cell is the in Figure 
4 shown glass slide with lanes; each lane binds two types of oligos at its 
surface. 
Figure 4: Illumina Flow Cell 
 
Source: Illumina 2018a 
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Figure 5: Sample Preparation 
 
Source: CeGaT 2018a 
 
Cluster Generation: Each fragment molecule binds to the first type of the two 
oligonucleotides on the flow cell surface by hybridization. This oligo is 
complementary to the adaptor region on one side of the strand. Then a 
polymerase creates a complement of one of the hybridized fragments. The 
double stranded molecule is denatured and the original template is washed 
away.  
The strands are clonally amplified by so-called bridge amplification: In this 
process, the strand falls over and the adaptor region on the other side of the 
oligo hybridizes to the second type of oligo on the flow cell. Polymerases 
generate the complementary strand, forming a double stranded bridge. This 
bridge is denatured, resulting in two single stranded copies of the molecules 
that are arising from the flow cell. The process is then repeated over and over 
again and occurs simultaneously for millions of clusters resulting in the clonal 
amplification of all the fragments. After amplification, the reverse strands are 
cleaved and washed off, leaving only the forward strands. The 3’-ends are 
blocked to prevent unwanted priming. 
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Figure 6: Cluster Generation on Flow Cell 
 
Source: CeGaT 2018b 
 
Sequencing begins with the forward strand (Read 1) by binding and extension 
of the forward primer. With each cycle, fluorescently tacked nucleotides 
compete for addition of the growing chain. Only one is incorporated, based on 
the sequence of the template. After the addition of each nucleotide, the 
clusters are excited by a light source and a characteristically fluorescence 
signal is emitted. The number of cycles determinates the lengths of the read. 
The emission wavelength along with the signal intensity determinates the 
identified base sequence. For a given cluster, all identical strands are read 
simultaneously. The Illumina HiSeq system is able to perform 5.3 - 6 billion 
reads per run. Thus, millions of clusters are sequenced at the same time. After 
the completion of the forward strand (Read 1), the complete read-product is 
washed away, the 3’-ends are deprotected and the template strand is again 
falling over and binding the second oligo on the flow cell. Polymerases extend 
the second flow cell oligo, forming a double stranded bridge, which then gets 
linearized and the 3’-ends are blocked. The original forward strand is cleaved 
off and washed away, leaving only the reverse strand. The sequencing of the 
reverse strand (Read 2) begins with the introduction of the reverse primer, as 
with Read 1. Sequencing steps are repeated and the desired read length is 
achieved. 
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Figure 7: Sequencing 
 
Source: CeGaT 2018b 
 
Data Analysis: This sequencing process generates billions of reads, 
representing all the fragments. Sequences from the whole process are 
collected and compared. Reads with similar overlapping base sequence, are 
locally clustered and paired creating continuous sequences, which are aligned 
back to the reference genome for variant identification. Source: (Illumina 2018b, c) 
 
To identify pathogenic variants in new FPC susceptibility genes out of 
thousands of detected genetic variants, the sequencing results have been 
sorted by using the following algorithm: 
i. Removing old controls (If older healthy family members carry a 
mutation, disease causing can be assumed as unlikely to be) 
ii. Only missense/splice site mutations or stop-gains/losses as more 
severe mutations 
iii. Mutation is present in PC patients 
iv. CADD(PHRED)-Score > 10 (defining a strong segregation of mutation 
with the disease) 
v. Low population frequency 
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By using this algorithm, several candidate genes with initially unknown 
significance have been identified. 
Another 12 FPC patients from different families have been included in the 
WGS-project to increase the number of candidate genes. As only one patient 
per family was sequenced, it was not possible to use the algorithm explained 
above because it is not possible to compare the detected variants without other 
sequenced family members. Thus, the sequencing data has been compared 
with reference sequences in particular from cancer driver genes and potential 
FPC susceptible genes known from earlier studies and literature to identify 
SNPs or INDELs with disease causing potential (BRCA1/2, PALB2, CDKN2A, 
CHEK2, ATM, TP53, STK11, MLH1, MSH2, MSH6, PMS2, PRSS1, PRSS2). 
 
2.5 Deleterious tests 
Missense variants are tested by MutationTaster, PolyPhen-2, SIFT and 
PROVEAN to identify their disease causing potential; at least 3 tools, which 
are based on different data, should be positive to expect deleteriousness. 
 
2.5.1 MutationTaster 
MutationTaster uses a ‘Bayes classifier’ to eventually predict the disease 
potential of an alteration. The ‘Bayes classifier’ is fed with the outcome of all 
tests and the features of the alterations and calculates probabilities for the 
alteration to be either a disease causing mutation or a harmless polymorphism. 
For this prediction, the frequencies of all single features for known disease 
mutations/polymorphisms were studied in a large training set composed of 
>390,000 known disease mutations from Human Gene Mutation Database 
(HGMD) and >6,800,000 harmless Single Nucleotide Polymorphism (SNPs) 
and Insertions/Deletions (INDEL) from the 1000 Genomes Project. 
The probability value is the probability of the prediction, a value close to 1 
indicates a high 'security' of the prediction. 




PolyPhen-2 (Polymorphism Phenotyping v2) is a tool similar to 
‘MutationTaster’, which predicts possible impact of an amino acid substitution 
on the structure and function of a human protein using straightforward physical 
and comparative considerations. 
(Adzhubei et al. 2010) 
 
2.5.3 SIFT 
SIFT (Sorting Intolerant From Tolerant) predicts whether an amino acid 
substitution affects protein function. SIFT prediction is based on the degree of 
conservation of amino acid residues in sequence alignments derived from 
closely related sequences, collected through 'Position-Specific Iterative Basic 
Local Alignment Search Tool' (PSI-BLAST).  
SIFT takes a query sequence and uses multiple alignment information to 
predict tolerated and deleterious substitutions for every position of the query 
sequence. SIFT is a multistep procedure that searches for similar sequences, 
chooses closely related sequences that may share similar function to the query 
sequence, obtains the alignment of these chosen sequences, and calculates 
normalized probabilities for all possible substitutions from the alignment. 
SIFT-Score: Ranges from 0 to 1. The amino acid substitution is predicted 
damaging if the score is ≤ 0.05, and tolerated if the score is > 0.05. 
Median Info: Ranges from 0 to 4.32, ideally the value would be between 2.75 
and 3.5. This is used to measure the diversity of the sequences used for 
prediction. 
(J. Craig Venter Institute 2018b) 
 
2.5.4 PROVEAN v1.1 
PROVEAN (Protein Variation Effect Analyzer) was developed as an 
advancement of SIFT and is also used to predict whether a protein sequence 
variation affects protein function. This tool is able to provide predictions for any 
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type of protein sequence variations including single or multiple amino acid 
substitutions, insertions or deletions. 
PROVEAN introduces a ‘delta alignment’ score based on the reference and 
variant versions of a protein query sequence with respect to sequence 
homologs collected from the ‘National Center for Biotechnologiy Information’ 
(NCBI) non redundant protein database through BLAST. The PROVEAN score 
distribution of a set of 58,000 ‘UniProt’ human protein variants with known 
functional outcome. For maximum separation of the deleterious and neutral 
variants, the cut-off is currently set at -2.5 (deleterious vs. neutral). 
(J. Craig Venter Institute 2018a) 
 
2.6 Exon Polymerase Chain Reaction (PCR) Amplification 
A Polymerase chain reaction (PCR) was used for specific amplification of ATM 
exons and surrounding regions including the splice sites for following 
sequence analyses. Each sample contained the listed ingredients. 
 
Table 7: PCR Samples 
PCR samples 
(in 0.2ml PCR tubes) 
Volume 
PCR Mastermix 10μl 
Primer forward 1μl 
Primer reverse 1μl 
DNA 30ng 
dH2O add to 20μl 
 
At 95°C DNA double strands are denaturing, so that the hybridization of the 
named primers (2.1, Table 5) can occur at lower temperature on 
complemented sequences at the 3’-end of each strand. Stable hydrogen 
bonds between complementary bases are formed only when the primer 
sequence matches the template sequence. The DNA-Taq-polymerase binds 
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to the primer-template hybrid and begins DNA elongation at 72°C in 5’-to-3’-
direction. The process then repeats, starting with denaturation of the template 
DNA and the synthesized DNA. After 35 cycles, the final elongation lasts 5 
minutes to complete the polymerization and in the end the cycler cools down 
to 4°C to hold ready for storage. 
Table 8: PCR Cycler Adjustment 
PCR cycler adjustments Time Temperature 
1. Denaturation 5 min 94°C 
2. Denaturation 30 sec 94°C 
3. Annealing 30 sec Depending on the structure of 
the used primers 
4. Elongation 30 sec 72°C 
Repeat steps 2 – 4 for 35x   
5. Elongation 5 min 72°C 
6. Pause ∞ 4°C 
 
The PCR amplification success was tested before sequencing by running an 
agarose gel (2% agarose in 100ml TBE buffer, 7μl peqGREEN) for 40 minutes, 
using the 50bp GeneRuler as a size marker to control the length of the 
amplicon and 5μl of each PCR product sample, including a negative control 
(no DNA), a positive control (amplicon of wildtype DNA) and the amplified 
amplicons of interest, each sample being mixed with 1μl of 6x DNA Loading 
Dye. 
 
2.7 Sanger Sequencing 
Sanger Sequencing was performed to detect potentially existent smaller DNA 
mutations, such as point mutations or INDELs of a few nucleotides in the 
amplified DNA from exons and splice sites flanking the exonic region. In total, 
30 FPC patients have been analysed by Sanger Sequencing. 
Sanger sequencing was performed by the Helmholtz Institut in München and 
Seqlab Microsynth (Göttingen, Germany) with ‘Barcode Economy Run’. The 
 32 
synthesized amplicon of interest (5μl), was treated in a 200μl tube, with 1μl 
alkaline Phosphatase and 1μl Exonuclease I and incubated in a PCR thermal 
cycler using the ‘Rapid PCR Cleanup’ program (5 minutes at 37°C, 10 minutes 
at 80°C, finally cooling down to 4°C). The product of the clean-up process was 
transferred to a 1.5ml tube, containing 6.5μl dH2O and 1.5μl forward primer 
(c= 20pMol/μl), which had been used for the PCR amplification. 
The sequencing method, developed in 1977 by Frederick Sanger and 
colleagues (Sanger, Nicklen, and Coulson 1977), is based on the incorporation 
of chain-terminating dideoxynucleotidetriphosphates (ddNTPs) by the DNA 
Polymerase during in vitro DNA replication. Here it was chosen to validate the 
Whole Genome Sequencing (WGS) results and search for further mutations in 
exonic DNA of the ATM gene as it is a reliable and moderately priced method. 
The sample contained the DNA template/amplicon to be sequenced, the DNA 
Polymerase, a DNA primer, normal deoxynucleosidetriphosphates (dNTPs) 
and fluorescently labelled ddNTPs, each of which emit light at different 
wavelengths. When dNTPs are incorporated to extend the synthesized DNA 
strand, the DNA-polymerase continues working. Whenever ddNTPs are 
incorporated, DNA-polymerase stops working because of the missing 3'-OH 
group required for the formation of a phosphodiester bond between two 
nucleotides. Because ddNTPs get incorporated randomly, the synthesized 
DNA strand can be stopped after each nucleotide, and the strands produced 
can be arranged by their size in a capillary electrophoresis. Due to the 
differentially labelled four ddNTPs, the fluorescence detector can distinguish 
the wavelengths of the length-sorted chains. In the generated chromatogram, 
the DNA sequence is readable and can be analysed using the free 
chromatogram viewer ‘Chromas’ (Technelysium DNA Sequencing Software 
2018). 
 
2.8 Multiplex ligation-dependent Probe Amplification (MLPA) 
MLPA was performed to identify copy number variations (CNV) such as 
deletions or duplications e.g. of whole exons. We used an MLPA Kit from MRC-
Holland with ATM-specific probe mixes, as listed in section 2.1. 
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Figure 8: MLPA Reaction 
 
Source: MRC-Holland 2018 
 
For the MLPA we used about 100ng of DNA, extracted from the patient’s blood 
as described in section 2.3 and then proceeded according to the instructions 
in the ‘MLPA® General Protocol’ from MRC-Holland. 
The frequency of ATM deletions or duplications in AT patients is around 2-5% 
(Podralska et al. 2014, Cavalieri et al. 2008), whereas in breast cancer it is 
less than 0.1% (Susswein et al. 2016). 
The principle of MLPA as described in the MRC-Holland Protocol is based on 
a PCR amplification of up to 60 probes, each of which detects a specific DNA 
sequence of approximately 60nt in length. Starting with DNA denaturation of 
the sample, a mixture of MLPA probes is added next. Each MLPA probe 
consists of two oligonucleotides that must hybridise to immediately adjacent 
target sequences in the analysed region in order to be ligated into a single 
probe. Each probe in an MLPA probe mix has a unique amplicon length (green 
part of the oligonucleotide in Figure 8 illustrates the part with variable length), 
typically the whole amplicon ranges between 130-500nt. In the following PCR 
reaction, all ligated probes are amplified simultaneously using the same PCR 
primer pair (primer binding sites are marked black at the oligonucleotide in 
Figure 8). One PCR primer is fluorescently labelled, enabling the amplification 
products to be visualised during fragment separation through capillary 
electrophoresis. The relative height of each individual probe peak (blue) in the 
electropherogram, as compared to the relative probe peak (orange) height in 
various reference DNA samples, reflects the relative copy number of the 
corresponding target sequence in the sample. Thus, a deletion of one or more 
target sequences becomes apparent as a relative decrease in peak height, an 
increased relative peak height reflects an amplification of the target sequence. 
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The capillary electrophoresis was performed in ABI-Prism 310 Genetic 
Analyser, using FAM (6-fluorescein amidite) primer dye and a 47cm capillary 
with the following injection mixture (Table 9): 
Table 9: Injection mixture 
Injection mixture volume 
PCR reaction 0.75μl 
dH2O 0.75μl 
GS 500 LIZ size standard 0.5μl 
HiDi (highly deionized) formamide 13.5μl 
 
Before capillary electrophoresis, it is essential to heat the injection mixture for 
3 minutes at 86 °C and then cool for 2 minutes at 4°C. The initial settings for 
capillary electrophoresis are as follows, injection voltage: 1.6 kV, injection time: 
15seconds, filter set: D, polymer: POP4. 
Source: (MRC-Holland 2018) 
For the analysis of the MLPA capillary electrophoresis results, GeneMapper 




3.1 ATM-analyzed families 
In total there have been used 35 families for analysing the ATM gene 
concerning deleterious variants. All chosen families correspond to the above-
named FPC definition. In 12 families are no further tumour entities known than 
PDAC, the additional tumour entities to PDAC of all other families are listed in 
the Table 10. Family 02-5-0382 contains 4 PDAC cases, but 2 of them are a 
married couple without a genetic relationship, therefore the number of PDAC 
cases in family is listed as 3. Table 10 also contains the tests, which have been 
executed at the PDAC index patients out of the 35 analyzed families. 
 
Table 10: ATM-analyzed families 





Other tumours  
in family WGS 
Sanger 
Sequencing MLPA 






1 0 0 
2 09-2-0552 185 2  1 0 0 
3 25-1-000091 503 3 Gastric CA 1 1 1 
4 25-1-000172 696 3  0 1 1 




0 1 1 
6 25-1-000204 768 3  0 1 1 
7 25-2-000014 153 3 Colorectal CA 1 1 1 
8 25-2-000129 605 3 Prostate CA 1 1 1 
9 25-2-000193 748 2 
Breast CA, 
Oesophageal CA 
0 1 1 
10 25-2-000203 767 3 Colorectal CA 0 1 1 
11 25-2-000213 792 2 Colorectal CA 0 1 1 
12 25-3-000181 715 3 
Breast CA, 
Colorectal CA 
0 1 1 




0 1 1 
14 25-4-000005 31 4 Renal CA 0 1 1 
15 25-4-000046 299 3 
Colorectal CA, 
Oesophageal CA 
1 0 0 
16 25-4-000088 498 2  1 1 1 
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Other tumours  
in family WGS 
Sanger 
Sequencing MLPA 




1 1 1 
18 25-4-000175 701 3 
Breast CA, 
Colorectal CA 
0 1 1 
19 25-5-000067 427 4 Breast CA 1 0 0 
20 25-5-000196 756 3 
Breast CA, 
Prostate CA 
0 1 1 
21 25-5-000205 774 3  0 1 1 




0 1 1 
23 25-6-000078 481 3 Breast CA 1 1 1 
24 25-7-000100 523 4  1 1 1 
25 25-7-000170 54 5 
Cervial CA, 
Colorectal CA 
1 1 1 
26 25-7-000212 788 3  0 1 1 
27 25-8-000168 685 6 
Malignant 
Melanoma 
1 1 1 
28 25-8-000178 709 2 
Colorectal CA, 
Lung CA, Prostate 
CA 
0 1 1 
29 25-8-000183 718 4  0 1 1 
30 25-9-000044 298 3 
Malignant 
Melanoma 
1 0 0 
31 25-9-000056 363 5 Breast CA 0 1 1 




1 1 1 
33 25-9-000182 717 3  0 1 1 
34 25-9-000185 721 3  0 1 1 
35 25-9-000186 723 4  0 1 1 
     15 30 30 
 
3.2 Whole Genome/Exome Sequencing (WGS/WES) 
In total, genomic DNA from PC patients of 15 different FPC families have been 
sequenced. These patients were selected for WGS because they show the 
highest number of first-degree relative PDAC patients among the families with 
high total numbers of PDAC cases. The sequencing data has been compared 
to reference sequences of cancer driver genes and FPC susceptibility genes 
to identify possible pathogenic variants.  
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Interestingly, one FPC patient presented with a deleterious single base 
substitution (ATM:NM_000051, exon36, c.G5385T, p.W1795C), detected in 
exon 36 of the ATM gene which has been previously been described as 
deleterious (Roberts et al. 2012, Roberts et al. 2016). 
 
3.3 Sanger Sequencing 
The ATM mutation was detected in FPC patient with lab number 181 from 
family 02-5-0382. EDTA-treated blood was available from patient 181 (III-8) 
and his children 182 (IV-1) and 183 (IV-2). The parents (II-4/5) of the index 
patient (181) both had PDAC and died from this malignant disease. There was 
tissue from the patient's mother which was tested negative for the mutation 
described below, no tissue from the father (II-4) was available for molecular 
genetic analyses. The mother (II-5) died at the age of 58 (PDAC diagnosis 
age: 57) and the father (II-4) died at the age of 67 (PDAC diagnosis age: 66). 
In addition to his PDAC diagnosis, he also had a rectum carcinoma, diagnosed 
at the age of 56. 
The father (II-4) of the index patient (III-8) was one of four siblings. His brother 
(II-3) also succumbed to PDAC at the age of 63 and a daughter (III-6) of this 
brother had malignant melanoma. A sister (II-2) died of breast cancer at the 
age of 65 after diagnosis at the age of 60 (see Figure 9). 
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The index patient initially sequenced is indicated by the arrow. Current age (in 
years) or age at death is given below each figure. Family members who are 
heterozygous for the W1795C missense mutation are labelled in red. 
EDTA-treated blood was also available from the children (IV-1/2) of the index 
patient (III-8) and was used to perform Sanger Sequencing of the ATM gene. 
The actually healthy son 182 (age: 22, at the time of last contact) was detected 
also to be a carrier of this heterozygous mutation. There are no known cancer 
diagnoses or precursor lesions, which is not surprising due to the young age 
of the patient. The daughter 183 was diagnosed with Acute Lymphoblastic 
Leukemia (ALL) in 1989, 1993 and 1997 and she was curatively treated by 
allogenic bone marrow transplantation (BMT) from a male donor. Her EDTA-
treated-blood was taken in 2001 and Sanger Sequencing showed that both 
alleles from the daughter 183 carry the wildtype sequence, as shown in the 
chromatogram below (Figure 11). To clarify, whether the sequenced leukocyte 
DNA originated from the female person 183 or her male BMT donor, a PCR of 
an amplicon (349bp), located in the SRY gene on Y-chromosome was 
performed. Thereby it could be shown (Figure 10) that the analysed DNA 
contains a Y-chromosome and consequently originates from a man and cannot 
be used to rule out the mutation W1795C at the female person 183. 
 
Figure 10: SRY-Amplicon Agarose gel Picture 
 
Unfortunately, there was no other tissue available from 183 than the EDTA-
blood, thus, no further DNA analysis could have been performed. 
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The heterozygous point mutation (ATM:NM_000051, exon36, c.G5385T, 
p.(W1795C)), identified in WGS, was then validated with Sanger Sequencing. 
Corresponding to reference sequence NM_000051, there is a substitution from 
guanine to thymine in the mutated allele of exon 35 at position 5385 from start-
codon. The affected base triplet is thus changed from ‘TGG’ to ‘TGT’. In the 
encoded protein, this substitution leads to the incorporation of the amino acid 
cysteine (C) at position 1795, instead of tryptophan (W). This variant is a 
missense mutation that tested to be deleterious. In this case, the mutation 
leads to a loss of function in modified ATM kinase. The mutation is not yet 
listed with a specific phenotype based on this polymorphism in the NCBI 
database ClinVar, which is a public archive of relationships among sequence 
variations and human phenotypes (Landrum et al. 2014). 
Deleteriousness was proven to be pathogenic by results obtained with 
Mutation Taster, PolyPhen-2, SIFT and PROVEAN, from which all four tools 
predicted the variant to be deleterious: 
MutationTaster: According to the Ensembl transcript ID: ENST00000278616 
and single base exchange G5385T, MutationTaster predicts the variant to be 
disease causing, using the model: simple_aae, with a probability value of 
0.995. 
PolyPhen-2: The mutation W1792C in ATM kinase is predicted to be ‘probably 
damaging’ with a score of 1.000 (sensitivity: 0.00; specificity: 1.00). 
SIFT: According to sequence ENSP00000388058 with variant W1795C, SIFT 
predicts the mutation to be damaging with a SIFT Score: 0, the Median 
Information Content: 2.5, and 46 Sequences at position. 
PROVEAN: Variant W1795C is predicted to be deleterious with PROVEAN 
Score -8.942 (cutoff=-2.5). 
Even though using leucocyte DNA from EDTA-treated blood is very common, 
Roberts describes the possibility that somatic mutations in haematological 
malignancy driver genes can confound the findings of germline genomic 
sequencing studies in older populations (Roberts et al. 2016). However, the 
ATM mutation in patient 181 was also verified in his son’s DNA (182), so we 
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can assume that it is a germline mutation and not a somatic mutation 
originating in haematopoiesis. In contrast to this, the leukocyte DNA from 
person 183 could not be used to identify germline mutations as she has 
leucocytes with a male chromosome set, based on the BMT nine years before 
EDTA-blood was taken. Rare cases like this are only to be identified by WGS 
and MLPA, not by Sanger Sequencing of single genes on autosomes. 
Figure 11: Sanger sequencing results 
FPC patient 181: heterozygous single base substitution 
Family member 182: heterozygous single base substitution 
Family member 183: homozygous wild type 
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Besides this deleterious mutation, there have been detected 20 non-
pathogenic variants in exons and exon-surrounding regions of the ATM gene. 
Some variants have been further described and published with a reference 
number, as they have been detected in other genetically studies focussing on 
ATM gene. All identified variants have been confirmed by using the forward 
and reverse primer for sequencing. All variants and the sequenced family 
members (index patient with PDAC) with homozygous (homo) or heterozygous 
(het) affection are listed in the table below (Table 11: ATM Variants). Only one 
of the 30 sequenced patients does not carry any variants in the analysed parts 
of the gene (patient lab number: 523, family ID: 25-7-000100). 
In Table 10 is first named the affected exon (E) and the type of mutation with 
the affected amino acids in parentheses and its exact position. The leading 
sign (+/-) characterises the position downstream (-) or upstream (+) of the 
named exon, a number without mathematical sign defines the position in the 
exon starting from the beginning of the exon, the position from the start of the 
gene is put in parentheses. In case of amino acid change by the mutation, the 
single letter amino acid code is used to declare the change, the affected amino 
acid position is named in parentheses. Known reference numbers of ‘single 
nucleotide polymorphisms’ (refSNP), registered at NCBI, are listed at the end 
of the variant description. 
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  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20     
31 homo homo                 homo             homo     4 Renal CA 
54 het het                 het             het     5 
Colon CA,  
Cervix CA 
153 het het                 het het           het     3 Colon CA 
363 het het                 het het           het     5 Breast CA 
432 het het   homo     het het het homo         het     homo     2 Colon CA, MM 
481 het het                 het             het     3 Breast CA 
498 homo homo                 homo             homo   het 2   
503       homo         het   het   het het het     het     3 Gastric CA 
523                                         4   
562 
    het           het   het       het     het     4 
Breast CA,  


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20     
571                 het   het     het het     het     3 Colon CA, MM 
605 het het           het     het           het het     3 Prostate CA 
685 homo homo                 homo             homo     6 MM 
696 homo homo                 homo             homo     3   
701 homo homo       het         homo             homo   het 3 
Colon CA,  
Breast CA 
704 het het                 het             het     3 SCC 
709 
                het   het       het     het     2 
Colon CA, 
Prostate CA,  
Lung CA 
715 het het                 het             het     3 
Colon CA,  
Breast CA 
717 het het                 het             het     3   
718 het het                 het             het     4   

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20     
723 het het         het het     het   het         het     4   
735 het het           het het   homo     het het     homo     3 Breast CA, MM 
748 het het         het het         het         het     2 
Breast CA, 
Oesophagus CA 
756         het                               3 
Breast CA, 
Prostate CA 
767 het het                 het   het         het     3 Colon CA 
768 homo homo                 homo         het   homo     3   
774 het het                 het             het     3   
788 homo homo                 homo             homo     3   
792 het het         het het het   homo       het     homo     2 Colon CA 
 
3.4 Multiplex ligation-dependent probe amplification (MLPA) 
The same 30 FPC patients sequenced in Sanger Sequencing have been 
analysed with MLPA to detect INDELs. No variants were found in comparison 
the reference sequences.  
Figure 12 is the electropherogram of the index patient of family 47 as a typical 
regular example without abnormalities, created by GeneMapper 4.0 which was 
used to analyse the measured data. The relative height of each individual 
probe peak (blue) in the electropherogram, as compared to the size marker 
probe peak (orange) height in various reference DNA samples, illustrates the 
relative copy number of the target sequence in the sample. A deletion of one 
or more target sequences thus becomes apparent as decrease in peak height; 
an increased relative peak height stands for an amplification of the target 
sequence. 
The probe mixes (P041-B1 and P042-B2) each contain 45 MLPA probes with 
amplification products between 130 and 485nt in length including 34 probes 
for the ATM gene and 11 reference probes. Thus, we had a probe for each 
ATM exon, including one probe for intron 1, two probes for exon 1 and 61 and 
two probes for intron 61. The reference sequences contain nine quality control 
fragments generating amplification products between 64 and 105nt, four DNA 
Quantity Fragments (Q-fragments), three DNA Denaturation Fragments (D- 
fragments), and one chromosome X and one chromosome Y-specific 
fragment. A ‘no DNA control’ was added included in each run. 
The four Quantity Fragments (Q-fragments, at 64-70-76-82 nt) are complete 
fragments that do not need to hybridise to DNA or to be ligated to be amplified 
during PCR. The more sample DNA is added, the lower these become. That 
is why in the ‘no DNA control’ sample, only the four Q-fragments are visible.  
The two D-fragments (88nt and 96nt) detect sequences in exceptionally strong 
CG-regions, which are difficult to denature. When the 88nt and 96nt fragments 
are low, it indicates denaturation problems of the sample DNA, possibly due 
to the presence of an excess of salt in the DNA sample that can lead to false 
positive deletions. 
47 
The MLPA peak of a DNA sample without genomic abnormalities will be 
identical to that of the reference samples, which means Dosage Quotient (DQ) 
of ~1. For heterozygous deletions, DQ will be ~0.5, homozygous deletion 
without allele copies have a DQ=~0. At duplications of the allele of interest, 
DQ will increase to ~1.5 (3 copies, heterozygous duplication) or ~2 (4 copies, 
homozygous duplication). 
The GeneScan™ 500 LIZ® size standard has been used to analyse the size 
of amplified oligos after capillary electrophoresis in the range of 20-500nt (size 
standards: 35, 50, 75, 100, 139, 150, 160, 200, 250, 300, 340, 350, 400, 450, 
490 und 500nt). 
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The deleterious ATM mutation, detected in the WGS-project, was verified by 
Sanger-Sequencing as heterozygous point mutation. The substitution from 
guanine to thymine in the mutated allele leads to the incorporation of the amino 
acid cysteine instead of tryptophan. This variant is a missense mutation that 
tested to be deleterious with a loss of function in modified ATM kinase. 
Furthermore, Sanger sequencing of the germline DNA from a group of 30 
unrelated FPC patients detected no further pathogenic variants in the ATM-
gene. Besides this deleterious mutation, there have been detected 20 more 
variants in exons and exon-surrounding regions of the ATM gene, all of which 
were tested to be non-pathogenic in the deleterious tests. Some variants have 
been further described and published with a reference number, as they have 
been detected in other genetically studies focussing on ATM gene. 
The same 30 unrelated FPC patients, of whom coding DNA from the ATM-
gene had been sequenced by Sanger-Sequencing, were analysed by MLPA. 
Again no further pathogenic variant was detected. 
In total, we identified a deleterious mutation in the ATM-gene in 1 of 35 (2.9%) 
FPC families. Considering only the more severely affected FPC families with 
three or more PDAC cases, the prevalence of deleterious ATM mutations was 




Cancer related death is the second most common cause for disease related 
death in Germany and the western world. PDAC even stands out with the worst 
prognosis of all malignant cancers and in comparison to other entities, the 
PDAC prognosis has not improved significantly in the last years (Statistisches 
Bundesamt 2017). Approximately 10% of PDAC patients have an increased 
risk, because of a distinctive familial aggregation of malignancies, probably 
due to pathogenic variants in germline DNA (Fendrich, Langer, and Bartsch 
2014). In hereditary tumour syndromes the underlying deleterious germline 
mutations segregate with the disease. However, for FPC, there are only a few 
known susceptible genes, like BRCA1 (Al-Sukhni et al. 2008), BRCA2 (Murphy 
et al. 2002), CDKN2A (Slater, Langer, Fendrich, et al. 2010), PALB2 (Slater, 
Langer, Niemczyk, et al. 2010) and CHEK2 (Bartsch et al. 2006), where 
pathogenic variants cause the increased PDAC risk in the affected families. 
Even in families with known mutations in the FPC susceptibility genes, there 
is still an incomplete penetrance (Roberts et al. 2016). The hereditary 
background of tumour syndromes with increased PDAC risk is very 
heterogeneous. Several other tumour entities or organ dysfunctionalities 
combined with PC in one patient or in one family have been described. The 
genetic basis underlying disease susceptibility in the remaining 80 – 90% of 
FPC patients is unknown (Roberts et al. 2016). Defining further FPC 
susceptibility genes might be an approach to improve the poor prognosis of 
PDAC, as there might be possibilities for a specific cancer screening for earlier 
diagnosis (Cohen et al. 2018) and targeted therapies (Choi, Kipps, and 
Kurzrock 2016) that would complement surgical resection, now the only 
curative option in PDAC therapy. 
The search for new candidate genes conferring susceptibility to FPC or other 
hereditary tumour syndromes is performed with WGS. This method allows the 
analysis of the majority of human DNA, much more than just protein coding 
sequences, as these make up only 1% of human DNA (Liang et al. 2018). 
However, WGS projects that have been performed in recent years, were only 
able to confirm the low rate of the above named FPC susceptibility genes 
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(Roberts et al. 2016). ATM was described as a new FPC susceptibility gene, 
with mutations identified in the North American population with a frequency of 
2.4% (Roberts et al. 2012), as low as the other identified FPC susceptibility 
genes. Apart from that, WGS studies could not identify further candidate genes 
with a frequency comparable to the named FPC susceptibility genes. 
In our WGS-project, we identified the mutation c.G5385T/p.W1795C in the 
ATM gene in one family that was tested to be deleterious. We verified the 
mutation by Sanger Sequencing. 
Sanger Sequencing and MLPA of all 63 coding ATM exons were then used to 
analyse DNA from additional FPC families, as there is no one area of the ATM 
gene especially susceptible to mutations (Telatar et al. 1998, Rothblum-Oviatt 
et al. 2016). DNA from peripheral white blood cells has been used, knowing 
that detected mutations can originate from somatic mutations in 
haematopoiesis and therefore need to be confirmed in DNA from a second 
tissue or in other family members, before expecting it to be germline DNA. 
Within the further analysed families, we could show, that the frequency of 
ATM-mutations in the analysed German population is at 2.9%. Knowing that 
the genes responsible for the majority of cases with increased PDAC risk in 
FPC families are still to be discovered, it is a small but important fact that ATM 
joins the low number of FPC susceptibility genes.  
The MLPA did not uncover variants in German FPC patients. It was well 
known, that the frequency of INDELs in other tumour predisposing syndromes 
is quite low but variable. The frequency of ATM deletions or duplications e.g. 
in AT patients is around 2-5% (Podralska et al. 2014, Cavalieri et al. 2008), 
whereas in breast cancer this is less than 0.1% (Susswein et al. 2016). Even 
if the used population is small, it does not seem to be necessary to regularly 
screen FPC patients by MLPA of the ATM gene. 
It needs to be noted, that the ATM-mutations, detected in ‘North American 
population’, as well as in ‘German population’, have been identified in families 
with more cancer entities than just PC. The North American families described 
also included patients with breast cancer, colon cancer, lung cancer, prostate 
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cancer, uterine cancer, ovarian cancer, malignant melanoma and lymphoma 
(Roberts et al. 2012). None of these patients’ DNA was sequenced in this 
study, thus, whether these cancer patients also carry the ATM-mutation 
remains unknown. The German ATM-mutation family includes members with 
breast cancer, malignant melanoma and rectal cancer, as shown in the 
pedigree above (Figure 9). Unfortunately, there was no DNA available for 
mutation analysis from family members other than the index patient and his 
children. The parents of the index patient both died of pancreatic cancer, but 
it was not possible to identify, whether the germline mutation was inherited 
from the father’s or the mother’s side. Regarding the North American families, 
the ATM mutation might be the reason for the diversity of malignancies in the 
family on the father’s side of the index patient. It is important to detect and 
analyse further families with deleterious ATM mutations in germline DNA to 
identify a segregation of the mutation with the diagnosed cancers. This is the 
only way to define cancer entities that develop based on ATM mutations and 
to identify or exclude additional, mutated genes. 
The ATM gene is not the only gene with pathogenic variants that result in 
different tumour entities. The most common example is the BRCA2 gene that 
has been proven to be an FPC susceptibility gene (Murphy et al. 2002, Slater, 
Langer, Fendrich, et al. 2010), in addition to playing a role in the HBOC-
syndrome (Ford et al. 1998). The reason that some mutations in the BRCA2 
gene lead only to breast cancer and some to pancreatic and breast cancer is 
not yet clarified. 
Further studies in larger cohorts are needed to verify the frequency of ATM 
mutations in FPC families and to define the fact whether a single inherited 
heterozygous ATM mutation in germline DNA is able to cause this diversity of 
malignancies. Furthermore, it has to be determined, if mutations in certain 
regions of the ATM gene lead to an aggregation of only pancreatic cancer 
while families with different mutations have an aggregation of several different 
cancer entities. 
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As a consequence of including ATM to the FPC-susceptibility genes, further 
studies need first to identify, which influence routinely screening of FPC 
patients on pathogenic variants in ATM gene can achieve in clinical daily 
routine. Supposing, that single pathogenic variants in the named FPC-
susceptibility genes can cause the high PDAC risk in FPC-families, there 
should be an intensified screening of individuals carrying the mutation. There 
further should no screening necessary of wild type tested individuals, as they 
then seem to have the same risk as the ‘German population’, which is not 
regularly screened on PDAC because of the low prevalence of the disease and 
the rapidly growing tumour. The second point to be tested in future studies is 
the influence of identified pathogenic variants in ATM gene on therapeutic 
treatment. As explained above (4.4.6), there are several approaches in mostly 
cell cultural studies, which show the possibility of using the damaged ATM-
kinase in the tumour cells with chemotherapy to supplement the curative 
surgical treatment and the common chemotherapeutics with individualized 
drugs to improve the poor prognosis of PDAC.  
54 
5 Abstract 
Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second 
leading cause of cancer related death in Germany by 2030. Despite extensive 
research in recent years, PDAC still has a dismal prognosis. About 5-10% of 
PDAC cases accumulate in families, due to the familial pancreatic cancer 
syndrome, other hereditary cancer syndromes or hereditary pancreatic 
dysfunctionality syndromes. Families with at least two first-degree relatives 
affected with PDAC without fulfilling the criteria of other cancer syndromes are 
defined as familial pancreatic cancer (FPC). So far BRCA1, BRCA2, CDKN2A, 
PALB2, CHEK2 have been identified as susceptibility genes for FPC, but 
predisposing germline mutations in these genes have been identified in only 
about 10% of FPC families. Previously, it was hypothesized that the Ataxia 
telangiectasia mutated (ATM) gene might also be a low penetrance FPC 
susceptibility gene. 
Therefore, we analysed 35 FPC families of the National Case Collection for 
familial pancreatic cancer (FaPaCa) registry by Whole Genome Sequencing, 
Sanger Sequencing and Multiplex ligation-dependent probe amplification 
(MLPA) to determine the role of ATM in FPC. A deleterious ATM germline 
mutation (X175Y) was detected 1 of these 35 FPC families according to a 
prevalence of 2.9%. Deleteriousness of the mutation tested positively using 
MutationTaster, PolyPhen2, SIFT and PROVEAN.  
ATM can be considered as a low penetrance FPC susceptibility gene, which 
might also predispose to other cancers despite PDAC. Further studies are 




6 German Abstract 
Das duktale Adenokarzinom des Pankreas (PDAC) gewinnt in Deutschland 
und der westlichen Welt zunehmend an Bedeutung. Das ‘Deutsche 
Statistische Bundesamt’ prognostiziert bis 2030 eine Zunahme zur 
zweithäufigsten krebsbedingen Todesursache, denn trotz intensiver 
Forschung der letzten Jahre hat das Pankreaskarzinom weiterhin eine 
schlechte Prognose. Bei 5-10% der Patienten mit malignen Neoplasien des 
Pankreas, deckt die Anamnese weitere PDAC Fälle unter erstgradig 
Verwandten auf, weshalb bei der insgesamt sehr niedrigen Prävalenz dieser 
Erkrankung von einem erhöhten familiären Risiko mit weitgehend ungeklärtem 
molekularen Hintergrund gesprochen werden kann. Diese familiäre Häufung 
kann auf das ‘familiäre Pankreaskarzinom’ (FPC), andere hereditäre 
Karzinom-Syndrome oder Syndrome mit Dysfunktionalität des Pankreas mit 
daraus resultierender erhöhter Karzinomneigung zurückgeführt werden. 
Per Definition müssen beim FPC mindestens zwei erstgradig Verwandte am 
Pankreaskarzinom erkranken, ohne dass sie gleichzeitig die Kriterien für ein 
anderes Tumorsyndrom erfüllen. Mutationen in den Genen BRCA1, BRCA2, 
CDKN2A, PALB2 und CHEK2 konnten in anderen Studien für die erhöhte 
Pankreaskarzinom Inzidenz in wenigen betroffenen Familien verantwortlich 
gemacht werden. In 80 - 90% der Familien sind in den genannten Genen keine 
Mutationen nachweisbar, deshalb bleibt hier die molekulare Ursache für das 
erhöhte Risiko weiterhin unklar. 
Die Suche nach Mutationen im ATM Gen in 35 FPC Familien sollte klären, ob 
das, bereits als potentiell relevantes FPC-Gen beschriebene, ATM-Gen in die 
Liste der FPC-Gene aufgenommen werden kann. Hierfür wurde Leukozyten-
DNA aus EDTA-Blut der FPC-Patienten mit ‘Whole Genome Sequencing’, 
‘Sanger Sequencing’ und ‘MLPA’ auf Mutationen im ATM Gen untersucht. In 
einer von 35 Familien (2.9%) wurde eine pathogene Mutation identifiziert, 
deren Funktionsverlust für die ATM-Kinase mittels MutationTaster, 
PolyPhen2, SIFT und PROVEAN bestätigt werden konnte. Mit einer 
Mutations-Prävalenz von 2,9% in FPC-Familien der untersuchten Population 
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reiht sich ATM bei den bereits anerkannten FPC-Genen mit ihrer ebenfalls 
niedrigen Prävalenz ein. Zukünftige Studien müssen die Korrelation zwischen 
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